12 results about "Cyclic lipopeptide" patented technology

The invention relates to the technical field of microorganisms, in particular to bacillus velezensis NEAU-L05, application of the bacillus velezensis NEAU-L05, antibacterial cyclic lipopeptide Iturin A and application of the antibacterial cyclic lipopeptide Iturin A. The bacillus velezensis NEAU-L05 disclosed by the invention is preserved in the China General Microbiological Culture Collection Center, the address is Institute of Microbiology, Chinese Academy of Sciences, 3 #, 1 # yard, West Beichen Road, Chaoyang District, Beijing, the preservation date is December 19, 2024, and the preservation number is CGMCC No.33130. The bacillus velezensis NEAU-L05 disclosed by the invention can be used for preparing the bacillus velezensis NEAU-L05. The bacteriostasis rate of the bacterial strain to botrytis cinerea of phytopathogen is 67.2%. The bacteriostatic cyclic lipopeptide ItuinA separated from the strain can improve the storage performance of berries, and a basis is provided for development of multiple biocontrol microbial agents with excellent performance.

The present invention discloses a cyclic lipopeptide carrier for encapsulating nucleic acid drugs, comprising a cyclic lactone structure formed by a heptapeptide R1R2R2R3R1R2R2 and a β-hydroxy fatty acid with a carbon chain length of 6 to 44, and its general structural formula is as follows: #imgabs0# wherein R1 is a basic amino acid, including one of histidine His, lysine Lys or arginine Arg, R2 is one of the hydrophobic amino acids leucine Leu, isoleucine Ile or valine Val, and R3 is one of any amino acid; n is an integer of 2 to 40; the positively charged basic amino acids in the cyclic lipopeptide bind to the negatively charged nucleic acid drug through electrostatic interaction to form cyclic lipopeptide-nucleic acid particles. The cyclic lipopeptide carrier for encapsulating nucleic acid drugs provided by the present invention has high safety, can effectively protect nucleic acid drugs, improves their stability, and has good transfection efficiency for a variety of cells, and has broad application prospects in the field of nucleic acid drug delivery.

The invention belongs to the technical field of biological extracts and cosmetics, and discloses a leukocyte extract composition as well as a preparation method and application thereof. The leukocyte extract composition comprises the following components in percentage by mass: 5-20% of a leukocyte extract; 3-10% of sodium surfactin; 10-20% of a humectant; and 50-82% of water. The preparation method of the leukocyte extract composition comprises the following preparation steps: adding the sodium surfactin into hot water at 50-80 DEG C for dissolving, then adding the humectant, homogenizing, stirring and uniformly mixing, cooling to room temperature, then adding the leukocyte extract, stirring and uniformly dissolving to obtain the leukocyte extract composition. According to the composition, a specific cyclic lipopeptide compound, namely, sodium surfactin, is adopted as a synergistic stable synergist of the leukocyte extract, so that the activity stability of the leukocyte extract can be remarkably improved, and better and more stable anti-aging, repairing and whitening effects can be achieved under the condition of smaller addition amount.

This invention discloses a cyclic lipopeptide delivery system, comprising a cyclic lipopeptide carrier and nucleic acid; the head of the cyclic lipopeptide carrier is composed of heptapeptides R1R2R2R3R4R2R2 linked together by amide bonds to form a ring, and the hydrophobic tail of the cyclic lipopeptide carrier is composed of a fatty acid with a carbon chain length of 6-44 forming an ester bond with the hydroxyl group on the head amino acid R3, with the following general structural formula: where R1 is a basic amino acid, including one of histidine (His), lysine (Lys), or arginine (Arg); R2 is a hydrophobic amino acid, including one of leucine (Leu), isoleucine (Ile), or valine (Val); R3 is a hydrophilic amino acid, including one of tyrosine (Tyr), serine (Ser), or threonine (Thr); R4 is one of glutamate (Glu) or glutamine (Gln); n is an integer from 5 to 43; the cyclic lipopeptide carrier encapsulates the nucleic acid drug to form cyclic lipopeptide-nucleic acid nanoparticles.

The present invention discloses a strain of Nocardia YINM00009 and its application in the preparation of cyclic lipopeptide compounds, belonging to the field of microbial technology. The Nocardia YINM00009 is an endophyte of Polygonatum daturae in Kunming, Yunnan Province, and can metabolize a large number of novel cyclic lipopeptide compounds after fermentation; the fermentation step mainly includes: fermenting the strain under suitable culture conditions to obtain a fermentation broth, after solvent extraction and concentration, combined with column chromatography, 9 cyclic lipopeptide compounds can be prepared, the total concentration of the 9 cyclic lipopeptide compounds in the fermentation broth can reach 10.2~16.5mg / L, and the purity after extraction and separation can reach more than 99%, of which 2 cyclic lipopeptide compounds have strong anti-tumor cytotoxic activity. The method is low in cost, simple in process, and environmentally friendly, and can be used for the mass production and preparation of such cyclic lipopeptide compounds, which not only meets the needs of a low-carbon economy, but also lays the foundation for the production of cyclic lipopeptide compounds and the development of related products in the later stage.

The application relates to a preparation method of natural cyclic lipopeptide nano-encapsulates with high oil content, and the steps are as follows: natural emulsifiers, glycerol, oil and water are weighed, the natural emulsifiers comprise sodium subtilipetrol and polyglycerol-10 oleate; the natural emulsifiers and the glycerol are mixed and heated and stirred, the oil is added after being dissolved, and a gel phase is obtained; water is added to the gel phase until the gel phase is completely dispersed, and natural cyclic lipopeptide nano-encapsulates are obtained. The compounding and synergistic effect of the sodium subtilipetrol and the polyglycerol-10 oleate is used in the application, compared with two single emulsifiers, the oil loading content is improved and the particle size is reduced. The natural nano-emulsion with high oil content prepared by the application has the advantages of low emulsifier dosage, simple process, small particle size (less than 600 nm), high oil content (more than 20%) of the prepared nano-emulsion, strong stability, high active substance loading content, good penetration effect and the like, is suitable for most liquid oils, and has high application value in the field of cosmetics.

The invention discloses nocardia YINM00009 and application of the nocardia YINM00009 in preparation of cyclic lipopeptide compounds, and belongs to the technical field of microorganisms. The nocardia YINM00009 is an endophyte of polygonatum kingianum in Kunming of Yunnan province, and a large number of novel cyclic lipopeptide compounds can be metabolized after fermentation; the fermentation step mainly comprises the following steps: fermenting the strain under proper culture conditions to obtain fermentation liquor, extracting and concentrating through a solvent, and combining with column chromatography to prepare nine cyclic lipopeptide compounds, the total concentration of the nine cyclic lipopeptide compounds in the fermentation liquor can reach 10.2-16.5 mg / L, the purity can reach 99% or above after extraction and separation, and the cyclic lipopeptide compounds can be used for preparing the cyclic lipopeptide compounds. Wherein the two cyclic lipopeptide compounds have very strong anti-tumor cytotoxic activity. The method is relatively low in cost, simple in process and environment-friendly, can be used for mass production and preparation of the cyclic lipopeptide compounds, not only meets the requirements of low-carbon economy, but also lays a foundation for later production of the cyclic lipopeptide compounds and development of related products.

This invention relates to the field of bactericide technology, specifically to a celandine bactericide and its preparation method. The bactericide is composed of the following parts by weight: antibacterial active ingredient: 0.1-0.5 parts; functional microbial agent: 2-20 parts; carrier: 70-90 parts; wherein the antibacterial active ingredient is composed of celandine and N-aryl-3,4-dihydroisoquinoline derivative in a mass ratio of 1:(0.2-5). This application introduces iodine and bromohalogen atoms at specific positions of N-aryl-3,4-dihydroisoquinoline, enabling it to produce a significant synergistic antibacterial effect with celandine. Beneficial bacteria such as Bacillus amyloliquefaciens and Pseudomonas fluorescens can resist the effects of sub-inhibitory drug concentrations by secreting cyclic lipopeptides and upregulating efflux pumps. The technology of encapsulating the antibacterial active ingredient into a sustained-release unit and combining it with a carrier that adsorbs live bacteria significantly improves the retention rate of live bacteria, achieving a long-term balance between stable drug release and beneficial bacterial activity.

The invention discloses a cyclic lipopeptide compound as well as a preparation method and application thereof. The cyclic lipopeptide compound is a compound C76H135N17O17, and the structural formula of the cyclic lipopeptide compound is shown in the description. The preparation method comprises the following steps: fermenting seawater bacillus miller in a liquid culture medium, centrifuging the fermented liquid culture to obtain a cell culture, soaking the cell culture in acetone, ultrasonically crushing, repeatedly soaking and extracting by using a mixed solution of methanol and dichloromethane, merging extract liquor, and concentrating to obtain a fermented crude extract; and repeatedly extracting the crude extract by using a dichloromethane-water solution, collecting a dichloromethane component, purifying by using semi-preparative liquid chromatography by using an isocratic acetonitrile-water solution as a mobile phase, and collecting a specific absorption peak. The compound extracted from the fermentation product of the seawater bacillus miller has remarkable inhibitory activity on gram-positive bacteria, gram-negative bacteria and fungi, and has important value in research and development of antibacterial and fungal drugs.

The invention aims to provide a novel biological preservative based on barophila barophila and a preparation method of the novel biological preservative aiming at the problem that an active component extraction process is complex, the novel biological preservative comprises an active component A, an active component B and a microcapsule carrier, the active component A is a cyclic lipopeptide compound separated from barophila barophila sp.DP-2022-01 fermentation liquor, and the molecular formula of the active component A is C34H58N5O7; the active ingredient B is halogenated fatty acid which is separated from fermentation liquor of deep sea barophilic bacteria Shewanella sp.DP-2022-03, and the molecular formula of the halogenated fatty acid is C15H20C1O2; the microcapsule carrier is a gelatin-Arabic gum composite wall material in a mass ratio of 1: 1. The active component A (cyclic lipopeptide compound) inhibits gram-positive bacteria (such as listeria monocytogenes) by destroying the integrity of bacterial cell membranes, and the active component B (halogenated fatty acid) can interfere bacterial energy metabolism to inhibit gram-negative bacteria (such as escherichia coli); the combined use of the two can achieve the bacteriostasis rate of more than 95% on fungi such as staphylococcus aureus and candida albicans.

The present disclosure relates to a novel cyclic lipopeptide compound and a use thereof. More specifically, the present invention relates to a compound represented by chemical formula 1, an acceptable salt thereof, a stereoisomer thereof, a hydrate thereof, or a solvate thereof, and to an antibacterial or biofilm formation inhibiting composition comprising the compound, the acceptable salt thereof, the stereoisomer thereof, the hydrate thereof, or the solvate thereof as an active ingredient.

The invention discloses bacillus atrophaeus NB65, which is characterized in that the strain has relatively strong inhibitory activity on pathogenic bacteria of northern corn leaf blight and corn stalk rot, is separated from a deep-sea sediment sample in South China Sea, is preserved in China Center for Type Culture Collection on May 25, 2023, is called CCTCC for short, and has a preservation number of CCTCC M 2023819. The invention discloses a preparation method for producing two novel cyclic lipopeptides, i.e., iso-C16 [Ile7] surfactin (1) and iso-C14 [MeGlu1, Ile7] surfactin (2), by virtue of the novel cyclic lipopeptides, i.e., iso-C16 [Ile7] surfactin (1) and iso-C14 [MeGlu1, Ile7] surfactin (2). The bacillus atrophaeus NB65 is subjected to fermentation, acid precipitation, rapid column chromatography, high performance liquid chromatography preparation and other methods to separate six surfactin (1-6), and then the structure of the compound is determined through the technologies of spectral analysis, improved Marfe's, quantum chemistry calculation and the like. The bacillus atrophaeus NB65 and the two new compounds generated by the bacillus atrophaeus NB65 have the potential of serving as biological agents, surfactants and biological active pesticides for inducing plant disease resistance.